1
|
Chhawchharia A, Haines RR, Green KJ, Barnett TC, Bowen AC, Hammer KA. In vitro antibacterial activity of Western Australian honeys, and manuka honey, against bacteria implicated in impetigo. Complement Ther Clin Pract 2022; 49:101640. [PMID: 35868137 DOI: 10.1016/j.ctcp.2022.101640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Revised: 07/07/2022] [Accepted: 07/09/2022] [Indexed: 11/28/2022]
Abstract
Impetigo is a contagious skin disease caused by Staphylococcus aureus and Streptococcus pyogenes. Without treatment, impetigo may be recurrent, develop into severe disease, or have serious, life-threatening sequelae. Standard treatment consists of topical or systemic antibiotic therapy (depending on severity), however, due to antibiotic resistance some therapies are increasingly ineffective. In this study we evaluated the potential for honey as an alternative treatment for impetigo. A broth microdilution assay in 96-well microtitre trays was used to determine the minimum inhibitory concentrations (MICs) of six monofloral honeys (jarrah, marri, red bell, banksia, wandoo, and manuka), a multifloral honey and artificial honey against S. aureus (n = 10), S. pyogenes (n = 10), and coagulase-negative staphylococci (CoNS) (n = 10). The optical density (OD) of all microtitre tray wells was also determined before and after assay incubation to analyse whether sub-MIC growth inhibition occurred. Jarrah, marri, red bell, banksia, and manuka honeys were highly effective at inhibiting S. aureus and CoNS, with MIC50 values ranging from 4 to 8% w/v honey. S. pyogenes was also inhibited by these same honeys, albeit at higher concentrations (8-29% w/v). Wandoo and multifloral honeys had the least antibacterial activity with MICs of >30% (w/v) for all isolates. However, OD data indicated that sub-MIC concentrations of honey were still partially restricting bacterial growth. Our pre-clinical data indicate that honey may be a potential therapeutic agent for the routine treatment of mild impetigo, and we suggest that clinical trials would be appropriate to further investigate this.
Collapse
Affiliation(s)
- Ayushi Chhawchharia
- School of Biomedical Sciences, The University of Western Australia, Crawley, 6009, Australia
| | - Robbie R Haines
- School of Biomedical Sciences, The University of Western Australia, Crawley, 6009, Australia; Cooperative Research Centre for Honey Bee Products Limited (CRC HBP), 128 Yanchep Beach Road, Yanchep, 6035, Australia
| | - Kathryn J Green
- School of Biomedical Sciences, The University of Western Australia, Crawley, 6009, Australia; Cooperative Research Centre for Honey Bee Products Limited (CRC HBP), 128 Yanchep Beach Road, Yanchep, 6035, Australia
| | - Timothy C Barnett
- School of Biomedical Sciences, The University of Western Australia, Crawley, 6009, Australia; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, 6009, Australia
| | - Asha C Bowen
- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, 6009, Australia; School of Medicine, The University of Western Australia, Crawley, 6009, Australia; Department of Infectious Diseases, Perth Children's Hospital, Nedlands, 6009, Australia
| | - Katherine A Hammer
- School of Biomedical Sciences, The University of Western Australia, Crawley, 6009, Australia; Cooperative Research Centre for Honey Bee Products Limited (CRC HBP), 128 Yanchep Beach Road, Yanchep, 6035, Australia.
| |
Collapse
|
2
|
Kumar S, Anwer R, Azzi A. Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii. Microorganisms 2021; 9:microorganisms9102104. [PMID: 34683425 PMCID: PMC8541637 DOI: 10.3390/microorganisms9102104] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 09/18/2021] [Accepted: 09/21/2021] [Indexed: 12/12/2022] Open
Abstract
Acinetobacter baumannii is an opportunistic pathogen which is undoubtedly known for a high rate of morbidity and mortality in hospital-acquired infections. A. baumannii causes life-threatening infections, including; ventilator-associated pneumonia (VAP), meningitis, bacteremia, and wound and urinary tract infections (UTI). In 2017, the World Health Organization listed A. baumannii as a priority-1 pathogen. The prevalence of A. baumannii infections and outbreaks emphasizes the direct need for the use of effective therapeutic agents for treating such infections. Available antimicrobials, such as; carbapenems, tigecycline, and colistins have insufficient effectiveness due to the appearance of multidrug-resistant strains, accentuating the need for alternative and novel therapeutic remedies. To understand and overcome this menace, the knowledge of recent discoveries on the virulence factors of A. baumannii is needed. Herein, we summarized the role of various virulence factors, including; outer membrane proteins, efflux pumps, biofilm, penicillin-binding proteins, and siderophores/iron acquisition systems. We reviewed the recent scientific literature on different A. baumannii virulence factors and the effective antimicrobial agents for the treatment and management of bacterial infections.
Collapse
Affiliation(s)
- Sunil Kumar
- Department of Biotechnology, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala 133207, India;
| | - Razique Anwer
- Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317-4233, Saudi Arabia;
| | - Arezki Azzi
- Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317-4233, Saudi Arabia
- Correspondence:
| |
Collapse
|
3
|
Wu H, Feng H, He L, Zhang H, Xu P. In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii. Appl Biochem Biotechnol 2021; 193:3867-3876. [PMID: 34524633 DOI: 10.1007/s12010-021-03664-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 09/03/2021] [Indexed: 10/20/2022]
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) has been a common pathogen of nosocomial infections and severely threatened the public health for decades. Tigecycline is a new type of antibacterial glycylcycline and minocycline derivative and has been used to treat CRAB in clinical practice. However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear. A total of 216 CRAB isolates were collected from multiple body parts of different patients. The gene types of these isolates were analyzed and their resistance to carbapenems was determined by Etest. Broth microdilution method was utilized to evaluate the minimum inhibitory concentration (MIC) of each sample. Checkerboard screening technique was performed to demonstrate the synergistic effects of antibiotics and fractional inhibitory concentration index (FICI) was established. Therefore, the joint treatment of tigecycline and colistin (1:1) could effectively improve the sensitivity of AB to antibiotics. OXA-24-like isolates were more sensitive to the combination of tigecycline and amikacin. On the other hand, OXA-23-like isolates were more sensitive to the combination of tigecycline and colistin. Tigecycline exhibited synergistic effects with amikacin and colistin to inhibit CRAB.
Collapse
Affiliation(s)
- Hongbin Wu
- The Clinical Laboratory, Tianjin Fifth Central Hospital, No. 41 Zhejiang Road, Binhai New District, Tianjin, 300450, China.
| | - Heqiang Feng
- The Clinical Laboratory, Tianjin Fifth Central Hospital, No. 41 Zhejiang Road, Binhai New District, Tianjin, 300450, China
| | - Lijie He
- The Clinical Laboratory, Tianjin Fifth Central Hospital, No. 41 Zhejiang Road, Binhai New District, Tianjin, 300450, China
| | - Heping Zhang
- The Clinical Laboratory, Tianjin Fifth Central Hospital, No. 41 Zhejiang Road, Binhai New District, Tianjin, 300450, China
| | - Ping Xu
- The Clinical Pharmacy, Tianjin Fifth Central Hospital, No. 41 Zhejiang Road, Binhai New District, Tianjin, 300450, China
| |
Collapse
|